Biochemical Marker Panel for Cardiovascular Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing cardiovascular disease risk in patients, particularly those with type 2 diabetes, are inadequate, as existing biochemical markers do not provide significant predictive value for cardiovascular events.
Innovation Solution
The use of a panel of biochemical markers including Trefoil Factor 3, alpha-2-Macroglobulin, Vascular Endothelial Growth Factor D, Tamm-Horsfall Urine Glycoprotein, Kidney-Injury-Molecule-1, Hepatocyte Growth Factor Receptor, Neuropilin-1, and alpha-Glutathione-S-Transferase, either alone or in combination with other markers, to assess the risk of cardiovascular disease development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biochemical markers are used for risk prediction in type 2 diabetes patients, then the assessment method is simple and widely available, but the predictive accuracy for cardiovascular events is insufficient
Solution Approach 1:
The patent combines multiple previously unconnected biochemical markers (TFF3, alpha-2-Macroglobulin, VEGF-D, Tamm-Horsfall, KIM-1, HGF-R, Neuropilin-1, IGFBP-4, alpha-GST) into a unified risk assessment panel. This merging of markers from different biological pathways (mucosal protection, protease inhibition, angiogenesis, kidney injury, oxidative stress) creates a comprehensive assessment tool that overcomes the limitations of single-marker approaches while maintaining clinical applicability
2Reliability
If a comprehensive panel of novel markers is implemented, then the risk prediction accuracy improves significantly, but the cost and complexity of the assessment increases
Solution Approach 1:
The patent develops a multi-functional marker panel that serves multiple purposes: predicting cardiovascular risk in type 2 diabetes, identifying patients who would benefit from intensive lipid-lowering therapy, and assessing overall cardiovascular health status. This universal application approach justifies the increased complexity by demonstrating broad clinical utility across different patient management scenarios
3Loss of information
If traditional risk factors alone are used for cardiovascular assessment, then the evaluation is straightforward and easy to implement, but the predictive value for future cardiovascular events is limited
Solution Approach 1:
The patent segments the cardiovascular risk assessment into distinct biological domains represented by specific markers: mucosal integrity (TFF3), protease regulation (alpha-2-Macroglobulin), vascular remodeling (VEGF-D, HGF-R), kidney function (KIM-1, Tamm-Horsfall), angiogenesis (Neuropilin-1), and oxidative stress (alpha-GST). This segmentation allows comprehensive information capture while enabling targeted interpretation of specific pathological processes
Data Source
AI summary
The present invention relates to the assessment of the risk for development of a cardiovascular disorder. It discloses the use of biochemical markers in the assessment of the risk for development of a cardiovascular disorder. It also relates to the use of the biochemical markers or marker panels for the assessment of the risk for development of a cardiovascular disorder and to kits for performing the methods of the invention.